Investor relations
Investor relations
Angel Biotechnology has created a unique offering in the biopharmaceutical contract manufacturing arena. The Company has achieved this by providing clients with customised services to support their complete biopharmaceutical product development and clinical manufacture under one roof. This provides significant savings in time and cost to the client who does not have to transfer their project from one company to another, avoiding the risks that accompany such activities. In addition to its state-of-the-art clinical manufacturing facilities and process development laboratories, Angel has built a highly skilled management team to take the business forward. The Company now has the combination of resources and skills required to deliver on our business plan.
Angel's principal activity is the manufacture and supply of clinical grade materials for use in our clients' drug development work. We have invested in a highly experienced management team and extremely flexible facilities which allow Angel to provide creative, low-cost solutions for our clients. Our flexibility and service offering allow us to capitalise on new technologies and emerging trends within the industry, maximising market penetration.
We are providing specialist solutions for cell-based therapies, e.g. cellular therapies and stem cells. The market for these therapies is expanding and Angel is in an excellent position to capitalise and become a market leader in providing such specialist services. We have a number of contracts moving into cGMP production where we have provided the client with a customised solution which meets their needs and accelerates their route to clinic. We expect to grow this part of our business significantly over the next few years, creating a differentiated offering for potential clients.
GM notice
Key dates 2012
| 30 September | End of half 1 2012 |
| 31 March 2013 | End of financial year |
| July 2013 (tbc) | Annual General Meeting |
Financial reports
2011/2012
2010
2009
Regulatory announcements
- Resignation of Nominated Adviser
13/03/2013 - Appointment of administrators
11/02/2013 - Suspension - Angel Biotechnology Holdings Plc
08/02/2013
DISCLAIMERThis section of the Angel Biotechnology Holdings plc ("Angel") website (the "Website") and the documents contained herein have been provided by Angel and its advisers for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall they, or the fact of the distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information contained in this section of the Website has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Persons accessing this section of the Website should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this section of the Website is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. The information contained in this section of the Website is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Angel, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this section of the Website nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on the documents included in this section of the Website only. Any and all opinions expressed are subject to change without notice and Angel is under no obligation to update the information contained in this section of the Website. To the fullest extent permitted by law, none of Angel, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from the use of all or any part of the information contained in this section of the Website. The information contained in this section of the Website should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute "independent investment research" for the purposes of the Financial Services Authority ("FSA") rules. The individuals who prepared the information contained in this section of the Website may be involved in providing other financial services to the company or companies referenced in this information or to other companies who might be said to be competitors of the company or companies referenced in this section of the Website. The information contained in this section of the Website nor any copy of part thereof should not be accessed by a person in any other jurisdictions where its access may be restricted by law and persons into whose possession the information in this section of the Website comes should inform themselves about, and observe, any such restrictions. Access of the information contained in this section of the Website in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions. Neither the whole nor any part of the information contained in this section of the Website may be duplicated in any form or by any means. Neither should the information contained in this section of the Website, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Angel. This section of the Website is only directed at persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the FSA) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). The information contained in this section of the Website must not be acted on or relied upon by persons who are not relevant persons. For the purposes of clarity, the information contained in this section of the Website is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the FSA). By clicking the "I accept" link below and by accessing this section of the Website you agree to be bound by the above terms and conditions and confirm that you are a relevant person. If you do not accept these terms and conditions or you are not a relevant person, please do not use this section of the Website. |
|
| Accept | Decline |
DISCLAIMERThis section of the Angel Biotechnology Holdings plc ("Angel") website (the "Website") and the documents contained herein have been provided by Angel and its advisers for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall they, or the fact of the distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information contained in this section of the Website has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Persons accessing this section of the Website should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this section of the Website is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. The information contained in this section of the Website is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Angel, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this section of the Website nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on the documents included in this section of the Website only. Any and all opinions expressed are subject to change without notice and Angel is under no obligation to update the information contained in this section of the Website. To the fullest extent permitted by law, none of Angel, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from the use of all or any part of the information contained in this section of the Website. The information contained in this section of the Website should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute "independent investment research" for the purposes of the Financial Services Authority ("FSA") rules. The individuals who prepared the information contained in this section of the Website may be involved in providing other financial services to the company or companies referenced in this information or to other companies who might be said to be competitors of the company or companies referenced in this section of the Website. The information contained in this section of the Website nor any copy of part thereof should not be accessed by a person in any other jurisdictions where its access may be restricted by law and persons into whose possession the information in this section of the Website comes should inform themselves about, and observe, any such restrictions. Access of the information contained in this section of the Website in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions. Neither the whole nor any part of the information contained in this section of the Website may be duplicated in any form or by any means. Neither should the information contained in this section of the Website, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Angel. This section of the Website is only directed at persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the FSA) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). The information contained in this section of the Website must not be acted on or relied upon by persons who are not relevant persons. For the purposes of clarity, the information contained in this section of the Website is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the FSA). By clicking the "I accept" link below and by accessing this section of the Website you agree to be bound by the above terms and conditions and confirm that you are a relevant person. If you do not accept these terms and conditions or you are not a relevant person, please do not use this section of the Website. |
|
| Accept | Decline |
Contact us
for investor relations queries:
enquiries@angelbio.com
Our services
Along with the successful production of recombinants, Angel provides development and process scale-up strategies
